CN211675895U - Antibacterial transdermal drug delivery device - Google Patents
Antibacterial transdermal drug delivery device Download PDFInfo
- Publication number
- CN211675895U CN211675895U CN202020017315.8U CN202020017315U CN211675895U CN 211675895 U CN211675895 U CN 211675895U CN 202020017315 U CN202020017315 U CN 202020017315U CN 211675895 U CN211675895 U CN 211675895U
- Authority
- CN
- China
- Prior art keywords
- antibacterial
- microneedle
- drug delivery
- delivery device
- transdermal drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Media Introduction/Drainage Providing Device (AREA)
Abstract
The utility model discloses an antibiotic transdermal device of dosing, it includes the micropin base plate and evenly distributed in antibiotic micropin on the micropin base plate, antibiotic micropin include the micropin main part and coat in the antibiotic coating on the surface of micropin main part, antibiotic coating is last to go upCarrying ferrous chloride. Fe is produced in inflammatory tissue due to ferrous chloride2+And the inflammatory tissue contains a hydrogen peroxide compound, so that a Fenton reaction catalyzed by Fe is easy to occur, and hydroxyl radicals generated by the reaction can play an antibacterial and anti-inflammatory effect in local tissues, so that the micro-needle has an antibacterial and anti-inflammatory function, and the skin can be effectively prevented from being infected by bacteria after the micro-needle penetrates into the skin.
Description
Technical Field
The utility model relates to a technical field that doses transdermally especially relates to an antibiotic transdermal device of dosing.
Background
Transdermal Drug Delivery Systems (TDDS) are a class of formulations in which the drug passes through the skin and is absorbed by the capillaries into the systemic blood circulation to achieve effective blood levels to produce drug efficacy. Compared with other dosage forms, the transdermal drug delivery preparation has the advantages of avoiding the first pass effect of the liver and the side effect of the gastrointestinal tract, prolonging the effective action time, enabling patients to take drugs independently, and the like. However, the barrier of the stratum corneum layer of the skin limits the application of conventional transdermal drug delivery formulations.
The main mode of the micro-needle transdermal drug delivery is that hundreds of micro-needles are covered on a small area at the same time to pierce the stratum corneum of the skin, and then the drug enters the human body by virtue of the micro-needles, so that the purpose of transdermal drug delivery is finally achieved. The technique has an advantage in that the stratum corneum is pierced using the microneedle without touching the nerve terminal of a human, and thus the microneedle does not produce a painful sensation when it is pierced. The dosage can be effectively controlled by the micro-needle, and a stable administration environment is provided. Therefore, the microneedle transdermal delivery technology has higher application value in the current medical field.
Studies have shown that the micro-channels established in the stratum corneum when microneedles deliver vaccines and drugs transdermally can act as entry ports for bacteria, leading to skin infections. The literature "Gonz-lez garca Laura E, MacGregor Melanie N, Visalakshan Rahul Madathiparambil, Ninan Neethu, callaro Alex a, trinidadaportal bigail D, Zhao Yunpeng, Hayball a John D, Vasilev krasmiir. Donnelly et al studied the migration of bacteria in microchannels formed by simulated membrane material and showed that the bacterial migration in microchannels was an order of magnitude less than in hypodermic needle holes. However, the adhesion of the bacteria to the microneedles is an order of magnitude greater than that to the latter, which counteracts the reduction due to the smaller pores. It is necessary to maintain sterility of the microneedle insertion site to minimize the possibility of introducing microbial pathogens at the site of administration.
However, the existing microneedles do not have an antibacterial function, and after they penetrate into the skin, they are likely to cause skin redness, inflammation, etc., which are likely to cause bacterial infection of the skin.
Disclosure of Invention
The utility model aims to overcome the defects existing in the prior art and provide an antibacterial transdermal drug delivery device.
In order to achieve the above purpose, the utility model adopts the following technical scheme:
an antibacterial transdermal drug delivery device comprises a microneedle substrate and antibacterial microneedles uniformly distributed on the microneedle substrate, wherein the antibacterial microneedles comprise microneedle main bodies and antibacterial coatings coated on the surfaces of the microneedle main bodies, and ferrous chloride is loaded on the antibacterial coatings.
Fe is produced in inflammatory tissue due to ferrous chloride2+On the other hand, the inflammatory tissue contains hydrogen peroxide, so that Fe-catalyzed fenton reaction is likely to occur, and the specific mechanism is as follows:
Fe2++H2O2→Fe3++OH-+OH·
the hydroxyl free radical generated by the reaction can play an antibacterial and anti-inflammatory effect in local tissues, so that the micro-needle has antibacterial and anti-inflammatory functions, and the skin can be effectively prevented from being infected by bacteria after the micro-needle penetrates into the skin.
Preferably, the microneedle substrate and the microneedle body are made of polylactic acid, polyglycolide, pullulan, or polyanhydride. The raw materials are sufficient in source, renewable, pollution-free in production process and biodegradable, can realize circulation in nature, are ideal green high polymer materials, and are high in use safety.
Preferably, the microneedle substrate is made of the same material as the microneedle body. Therefore, the microneedle substrate and the microneedle main body are firmly connected, the microneedle main body is not easy to fall off, and the preparation is easy.
Preferably, the antimicrobial coating includes ferrous chloride and a ferrous chloride-loaded carrier.
Preferably, the material of the carrier is the same as that of the microneedle main body. Therefore, the antibacterial coating has better stability, can be firmly adhered to the microneedle main body and is not easy to fall off.
Preferably, the thickness of the antibacterial coating is 1 μm to 10 μm.
Preferably, the height of the microneedle body is 500 to 700 μm. When the microneedle main body is designed to be at the height, the microneedle main body can smoothly pierce the stratum corneum of the skin, ensures the transdermal drug delivery effect, ensures the drug delivery amount, cannot touch nerve endings, cannot generate pain, and can reduce the bleeding probability. More preferably, the height of the microneedle body is 600 μm. At the moment, the administration effect of the microneedle main body is better, no pain is caused, and the bleeding probability is lowest.
Preferably, the area of the microneedle substrate is 0.5cm2～10cm2. Preferably, the microneedle substrate has an area of 1cm2～5cm2. Preferably, the microneedle substrate has an area of 1cm2～3cm2。
In practical application, can design the area of micropin base plate according to the area of treating, nevertheless the area size of micropin base plate also can cause certain influence to the use, and the area of micropin base plate too greatly can be unfavorable for pasting and put on skin, needs to use more appurtenance fixed, and too little then can be unfavorable for the people to take. But at 0.5cm2～10cm2The area of the light source can meet the basic use requirement when being designed; at 1cm2～5cm2When the area size is designed, the use effect is better, and the patch is easy to stick and hold stably; at 1cm2～3cm2When the area size of the eye mask is designed, the eye mask is more suitable for the use of the eye mask and the skin for removing acnes, and the eye mask is generally used for 3cm2The acne removing amount is 1cm2In (1).
Preferably, the microneedle body is a solid conical structure.
Preferably, the distribution density of the microneedle main body on the microneedle substrate is 100-1000 roots/cm2。
The utility model discloses a manufacturing method of antibiotic transdermal drug delivery device, including following step:
(1) preparing a mould made of polydimethylsiloxane material according to the shape of the transdermal drug delivery device, placing the material in the mould, then placing the mould in a vacuum drying oven at 200 ℃ and 85KPa for 2 hours to completely melt the material, finally cooling the material to room temperature, and then demoulding to obtain a transdermal drug delivery device blank;
(2) dissolving a carrier material in tetrahydrofuran to obtain a carrier solution with the mass fraction of 2%, then adding a ferrous chloride aqueous solution, and uniformly mixing to obtain a carrier/ferrous chloride mixed solution. Uniformly smearing a carrier/ferrous chloride mixed solution on the surface of a microneedle main body of a transdermal drug delivery device blank in an aseptic environment, freezing the microneedle main body in a refrigerator at the temperature of-80 ℃ for 4 hours after smearing is finished, then soaking the microneedle main body in a cyclohexane solvent for 10 minutes, and finally carrying out vacuum drying treatment for 4 hours to obtain the antibacterial transdermal drug delivery device.
Compared with the prior art, the beneficial effects of the utility model reside in that: the utility model discloses an antibiotic transdermal drug delivery device is equipped with the antibiotic micropin that contains ferrous chloride, and this antibiotic micropin has antibiotic and anti-inflammatory action after stabbing human skin, has effectively reduced the risk that skin is infected by the bacterium.
Drawings
Fig. 1 is a perspective schematic view of the antibacterial transdermal drug delivery device of the present invention;
FIG. 2 is a schematic side view of the antimicrobial transdermal delivery device of the present invention;
fig. 3 is an axial sectional view of the antibacterial microneedle of the present invention.
In the figure, a microneedle substrate 1, an antibacterial microneedle 2, a microneedle main body 3, an antibacterial coating 4, ferrous chloride 5 and a carrier 6 are provided.
Detailed Description
For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to the accompanying drawings and specific embodiments.
Example 1
The embodiment provides an antibacterial transdermal drug delivery device, as shown in fig. 1-3, comprising a microneedle substrate 1 and antibacterial microneedles 2 uniformly distributed on the microneedle substrate 1. Specifically, the microneedle base plate 1 is a base for supporting the antimicrobial microneedles 2, and the shape thereof is not limited, and the shape thereof is designed to be rectangular in the present embodiment. The antibacterial microneedle 2 comprises a microneedle main body 3 and an antibacterial coating 4 coated on the surface of the microneedle main body 3, wherein the antibacterial coating 4 comprises ferrous chloride 5 and a carrier 6 loaded with the ferrous chloride 5.
The microneedle substrate 1, the microneedle body 3 and the carrier 6 of the antibacterial coating 4 of this embodiment may be made of polylactic acid, polyglycolide, pullulan or polyanhydride. The raw materials are sufficient in source, renewable, pollution-free in production process and biodegradable, can realize circulation in nature, are ideal green high polymer materials, and are high in use safety. In this embodiment, the microneedle substrate 1, the microneedle main body 3 and the carrier 6 are all made of polylactic acid, so that the microneedle substrate 1 and the microneedle main body 3 are firmly connected, the microneedle main body 3 is not easy to fall off and is easy to prepare, and the antibacterial coating 4 has good stability, can be firmly adhered to the microneedle main body 3 and is not easy to fall off.
In this embodiment, the thickness of the antibacterial coating layer 4 is 1 μm to 10 μm in order to ensure an effective antibacterial effect. In order to allow the microneedle to reliably administer the drug transdermally without touching the nerve and causing pain, the height of the microneedle body is 500 to 700 μm, preferably 600 μm. The area of the microneedle substrate was 0.5cm2～10cm2Preferably 1cm2～5cm2More preferably 1cm2～3cm2。
In this embodiment, the microneedle body 3 has a solid conical structure, and the distribution density of the microneedle body on the microneedle substrate 1 is 100-1000 roots/cm2. When the distribution density of the microneedle main body 3 is within the above range, the antibacterial transdermal drug delivery device has high strength, and can pierce the stratum corneum of the skin well to realize transdermal drug delivery.
The manufacturing method of the antibacterial transdermal drug delivery device comprises the following steps:
(1) preparing a mould made of polydimethylsiloxane material according to the shape of a transdermal drug delivery device, placing polylactic acid particles in the mould, then placing the mould in a vacuum drying oven at 200 ℃ and 85KPa for 2 hours to completely melt the polylactic acid particles, finally cooling the polylactic acid particles to room temperature, and then demoulding to obtain a transdermal drug delivery device blank;
(2) dissolving polylactic acid particles in tetrahydrofuran to obtain a polylactic acid solution with the mass fraction of 2%, then adding a ferrous chloride aqueous solution, and uniformly mixing to obtain a polylactic acid/ferrous chloride mixed solution. Uniformly smearing polylactic acid/ferrous chloride mixed solution on the surface of a microneedle main body of a transdermal drug delivery device blank in an aseptic environment, freezing the microneedle main body in a refrigerator at the temperature of-80 ℃ for 4 hours after smearing is finished, then soaking the microneedle main body in cyclohexane solvent for 10 minutes, and finally carrying out vacuum drying treatment for 4 hours to obtain the antibacterial transdermal drug delivery device.
The method of using the antibacterial transdermal drug delivery device of the present embodiment: diabetic patients take insulin every day, and the injection of insulin to patients causes fear of acupuncture and pain. Transdermal administration in the form of microneedles, although non-invasive, requires multiple successive administrations of insulin, which greatly increases the risk of bacterial infection after multiple insertions. Therefore, insulin is loaded on the microneedle substrate and the microneedle main body according to the conventional method, and administered to the patient, and whether the skin of the administration site of the patient is inflamed or broken is observed, thereby determining whether the antibacterial transdermal drug delivery device of the present embodiment is antibacterial. Meanwhile, a transdermal drug delivery device without an antibacterial coating was used as a control group.
It was observed that the skin of the patients administered with the antibacterial transdermal drug delivery device of the present embodiment did not show red swelling, skin breakage, etc., whereas the skin of the patients of the control group showed red swelling after administration of the drug several times. The antibacterial transdermal drug delivery device has good antibacterial and anti-inflammatory effects, and can effectively prevent the skin from being infected by bacteria.
Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that the technical solutions of the present invention can be modified or replaced with equivalents without departing from the spirit and scope of the technical solutions of the present invention.
Claims (10)
1. The antibacterial transdermal drug delivery device is characterized by comprising a microneedle substrate and antibacterial microneedles uniformly distributed on the microneedle substrate, wherein the antibacterial microneedles comprise microneedle main bodies and antibacterial coatings coated on the surfaces of the microneedle main bodies, and ferrous chloride is loaded on the antibacterial coatings.
2. The antibacterial transdermal drug delivery device according to claim 1, wherein the microneedle substrate and the microneedle body are made of polylactic acid, polyglycolide, pullulan or polyanhydride.
3. The antimicrobial transdermal drug delivery device according to claim 1, wherein the antimicrobial coating comprises ferrous chloride and a ferrous chloride-loaded carrier.
4. The antibacterial transdermal delivery device according to claim 3, wherein the material of the carrier is the same as that of the microneedle body.
5. The antibacterial transdermal drug delivery device according to claim 1, wherein the antibacterial coating layer has a thickness of 1 to 10 μm.
6. The antibacterial transdermal drug delivery device according to claim 1, wherein the height of the microneedle body is 500 to 700 μm.
7. The antimicrobial transdermal drug delivery device according to claim 1, wherein the microneedle substrate has an area of 0.5cm2～10cm2。
8. The antimicrobial transdermal drug delivery device according to claim 1, wherein the microneedle substrate has an area of 1cm2～3cm2。
9. The antimicrobial transdermal drug delivery device according to claim 1, wherein the microneedle body has a solid conical structure.
10. The antibacterial transdermal drug delivery device according to claim 1, wherein the distribution density of the microneedle main body on the microneedle substrate is 100-1000 roots/cm2。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020017315.8U CN211675895U (en) | 2020-01-03 | 2020-01-03 | Antibacterial transdermal drug delivery device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202020017315.8U CN211675895U (en) | 2020-01-03 | 2020-01-03 | Antibacterial transdermal drug delivery device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN211675895U true CN211675895U (en) | 2020-10-16 |
Family
ID=72799118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202020017315.8U Active CN211675895U (en) | 2020-01-03 | 2020-01-03 | Antibacterial transdermal drug delivery device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN211675895U (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113101515A (en) * | 2021-04-06 | 2021-07-13 | 广州联合丽拓生物科技有限公司 | Method for processing beauty needle |
-
2020
- 2020-01-03 CN CN202020017315.8U patent/CN211675895U/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113101515A (en) * | 2021-04-06 | 2021-07-13 | 广州联合丽拓生物科技有限公司 | Method for processing beauty needle |
| CN113101515B (en) * | 2021-04-06 | 2022-11-18 | 广州联合丽拓生物科技有限公司 | Method for processing beauty needle |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Preparation, properties and challenges of the microneedles-based insulin delivery system | |
| CN113491675B (en) | Microneedle wound plaster for preventing scars and preparation method thereof | |
| KR101747099B1 (en) | Method of Preparing Micro-Needle Using Biocompatible Polymer | |
| WO2022105824A1 (en) | Preparation method and application for microneedle carrying live bacteria | |
| CN102657914A (en) | Micro-needle transdermal delivery patch with high penetration efficiency | |
| CN107007927A (en) | A kind of microneedle array drug paste and preparation method being administered based on electric field driven | |
| CN112023033B (en) | Two-section micro-needle array patch for simultaneously realizing BCG vaccine inoculation and diagnosis and preparation method thereof | |
| Xue et al. | Drug-eluting microneedles for self-administered treatment of keloids | |
| CN112999297A (en) | Microneedle patch for scar treatment and preparation method thereof | |
| CN115252593A (en) | Local anesthesia microneedle array for dentistry | |
| CN211675895U (en) | Antibacterial transdermal drug delivery device | |
| CN111558128A (en) | Soluble microneedle array carrying scar repairing medicine and preparation method | |
| CN115920222A (en) | Microneedle and preparation method thereof, microneedle patch and preparation method thereof | |
| Long et al. | Microneedles for in situ tissue regeneration | |
| Zhuang et al. | Targeting Diverse Wounds and Scars: Recent Innovative Bio‐design of Microneedle Patch for Comprehensive Management | |
| An et al. | Novel microneedle platforms for the treatment of wounds by drug delivery: a review | |
| KR101779393B1 (en) | Microneedle array comprising nucleic acid and manufacture method thereof | |
| Jose et al. | Advances in microneedles-based drug delivery system on promoting wound healing | |
| CN114917465B (en) | Self-heating microneedle drug-loaded patch and preparation method thereof | |
| KR101927654B1 (en) | Coating Method of Micro-Needle and the Micro-Needle | |
| CN114177512B (en) | Antibacterial and healing-promoting soluble microneedle patch deposited layer by layer and preparation method thereof | |
| CN112999200B (en) | Transdermal drug delivery layer | |
| CN113521523A (en) | Microneedle drug delivery system for treating wound surface and application thereof | |
| CN108969879B (en) | Compound microneedle and microneedle patch | |
| CN113274372A (en) | Preparation method of microneedle patch for quickly and efficiently relieving itching due to mosquito bites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |